Remove 2014 Remove Medical science Remove Safety
article thumbnail

Moving towards oral delivery of biologics

European Pharmaceutical Review

Studies show that persistence and adherence are generally better for oral medications compared with injections. Importantly, we believe the safety, reliability, and pharmacokinetic data that we collected through both parts of the Phase I study support the initiation of a Phase II trial of RT-102 in osteoporosis,” Hashim said.

article thumbnail

Targeted therapies for chronic lymphocytic leukaemia in an evolving treatment landscape

European Pharmaceutical Review

BTKis, oral drugs given as continuous monotherapy, have revolutionised the treatment of CLL, with the first generation BTKi ibrutinib receiving European Medicines Agency (EMA) approval in 2014; however, side-effects (such as cardiovascular toxicities 2 ) have limited its suitability. for all-comers; HR=0.52

Safety 52